Could the mRNA technology that brought us rapid COVID vaccines open the door to

vaccines against a host of other pathogens? There are many we never had a vaccine,

not just that it took a long time. That's becoming more realistic than ever before.

Today's Monday, October 16th, and today is Science Friday.

I'm Sci-Fi producer Charles Berquist. mRNA technology caught the attention of

the Nobel Prize Committee this year, but it's a lot more than just updated

COVID boosters. The whole range of vaccines are under development from

everything from Lyme disease to cancer, all based on those advances in mRNA.

We'll talk about it. We'll also talk about an early trial of a triple vaccine

against measles, mumps, and COVID that's delivered through the nose. Here's

Iroflado. You've probably heard that there's an updated COVID vaccine on the

market, right? Maybe you have already gotten your booster, but there are new

kinds of vaccines and new approaches to them under development. I mean, what if

one dose could protect against several illnesses? And what if that dose didn't

have to be a shot, but a nasal spread? Joining me to talk about what researchers

are working on for both COVID and other diseases is Dr. Eric Topel. He's the

founder and director of the Scripps Research Translational Institute. He's

professor of molecular medicine and executive vice president of Scripps

Research in La Jolla, California. Welcome back, Eric, to Science Friday. Thanks,

Eric. Great to be with you again. Nice to have you. You recently wrote about a

trivalent nasal vaccine that showed efficacy against COVID strains, measles,

and mumps. Tell me about that. Sounds exciting. Yeah, it really is. I'm still

...